RxDoctor Payments Data

Lynda Nwabuobi

Neurology · Washington, DCNPI 1508276957

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,109, 2.0 times the $1,052 reported in 2019.

$6,276in general payments, 2019–2025

Across 234 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$600
  • Teva Pharmaceuticals USA, Inc.$525
  • Lilly USA, LLC$415
  • MDD US Operations, LLC$386
  • Neurocrine Biosciences, Inc.$294
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$6,276100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,276 in reported general payments places this provider in the 65th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$129,403
Medicare patients
325
Services billed
4,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Carbidopa-LevodopaCarbidopa/Levodopa155$3,360
Selegiline Hcl18$2,091
Memantine Hcl31$1,673
Carbidopa-Levodopa ErCarbidopa/Levodopa34$899
Mirtazapine15$645
Donepezil Hcl47$473
Gabapentin37$384
Pregabalin23$349
Clonazepam13$287
Propranolol Hcl12$268
Duloxetine Hcl23$208
AmantadineAmantadine Hcl11$192

Paid to pharmacies, not to this prescriber.

Other neurology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →